Chimeric Therapeutics (ASX:CHM) secured a US patent allowance for its CHM CDH17 chimeric antigen receptor technology, a CAR-T therapy targeting gastrointestinal cancers, according to a Tuesday filing with the Australian bourse.
The patent application is for compositions and methods for retrieving tumor-related antibodies and antigens, the filing said.
The patent allowance is expected to provide patent protection until at least 2039.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.